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Abstract There has been a large increase in the incidence of invasive fungal infec-
tions (IFIs) over the past decades, largely because of the increasing size of the
population at risk. One of the major risk groups for IFIs are patients with
haematological malignancies treated with cytotoxic chemotherapy or un-
dergoing haematopoietic stem cell transplantation. These IFIs are associated
with high morbidity and mortality rates. Consequently, as the diagnosis of
IFIs is difficult, antifungal prophylaxis is desirable in high-risk patients.
Furthermore, as the economic impact of IFIs is also significant, it is im-
portant to assess the cost benefit and cost effectiveness of each prophylactic
agent in order to aid decisions concerning which prophylactic agent provides
the best value for limited healthcare resources. This article systematically
reviews the available pharmacoeconomic evidence regarding antifungal pro-
phylaxis in immunocompromised patients treated for haematological malig-
nancies. Furthermore, specific points of interest concerning economic analyses
of antifungal prophylaxis are briefly discussed.
Considering the available evidence, antifungal prophylaxis in immuno-
compromised patients treated for haematological malignancies seems to be
an intervention with favourable cost-benefit, cost-effectiveness and cost-
saving potential. Furthermore, recently introduced antifungal agents seem to
be attractive alternatives to fluconazole from a pharmacoeconomic point of
view. However, due to wide heterogeneity in patient characteristics, under-
lying diseases, hospital settings and study methods in the included economic
studies, as well as the lack of ‘head-to-head’ trials, it is difficult to find clear
evidence of the economic advantages of a single prophylactic agent. Fur-
thermore, we show that the results of cost-effectiveness analyses are highly
dependent on several crucial factors that influence the baseline IFI incidence
rates and, therefore, differ per patient population or region.
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There has been a large increase in the incidence
of invasive fungal infections (IFIs) over the past
decades, largely because of the increasing size of
the population at risk.[1-4] One of the major risk
groups for IFIs are patients with haematological
malignancies treated with cytotoxic chemotherapy
or undergoing haematopoietic stem cell trans-
plantation (HSCT).[3,4] Improvements in supportive
care, increasing numbers of HSCTs, increased use
of antibacterials and more intensive regimens have
resulted in more profound levels of immuno-
suppression in these patients, leading to a higher
susceptibility for IFIs. Although incidence rates
of IFIs vary considerably among countries and
institutions, overall incidence rates of 5–40%
have been reported in acute leukaemia andHSCT
patients.[3,5-7]
In Europe and North America, the main cau-
sative agents are Aspergillus and Candida species.
However, in recent years, the epidemiology of yeast
infections has changed substantially. Although
Candida albicans is still commonly encountered,
a shift has been observed toward non-albicans
species.[8-10] Unlike the total incidence of yeast in-
fections, which appears to remain stable, the in-
cidence of mould infections is still increasing.[11,12]
These mould infections are mainly caused by
Aspergillus species.
These IFIs are associated with significant mor-
bidity and mortality. In particular, forAspergillus
infections, very high mortality rates of 60% have
been reported.[13] Furthermore, the economic im-
pact of IFIs is significant.Wilson et al.[14] assessed
the direct and indirect costs of IFIs in patients
with different underlying conditions. They esti-
mated that the average per-patient cost attribu-
table to an IFI during the first year, in 1998, was
$US31 193. Among the different types of fungi,
Aspergillus infections were estimated as the most
costly to treat, with an incremental cost per patient
of $US72792. Furthermore, recently, Jansen et al.[15]
estimated the cost per patient for treating invasive
aspergillosis in the Netherlands in 2005. They
reported a mean total treatment cost of approxi-
mately h30 000 per patient.
The general management of IFIs can be divided
into four main strategies:[16] (i) prophylaxis;
(ii) empirical therapy for at-risk patients with signs
of infection of unclear aetiology (usually persistent
fever) despite treatment with broad-spectrum anti-
bacterials; (iii) pre-emptive therapy for high-risk
patients whose signs, symptoms or diagnostic tests
are suggestive of an (incipient) IFI; and (iv) direc-
tive treatment of a proven or probable infection.
Antifungal drugs applicable in the clinical setting
belong to three major categories: (i) the polyenes,
of which amphotericin B desoxycholate is the pro-
totype that has been replaced by the newer, less
toxic, but more expensive, liposomal amphotericin
B (L-AmB) [AmBisome and Abelcet]; (ii) the
azoles, such as fluconazole, itraconazole, vori-
conazole and posaconazole; and (iii) the echino-
candins, such caspofungin, anidulafungin and
micafungin. Although diagnostic tests have im-
proved, even, to date, early diagnosis of IFIs
remains very difficult.[11,17] Together with a con-
siderable failure rate of IFI treatment associated
with significant morbidity and mortality, this has
resulted in a considerable increase in the use of
prophylactic and empirical antifungal strategies
in high-risk patients in daily practice during re-
cent years.[18,19]
In many institutions, the main antifungal agent
used for prophylaxis has been fluconazole. How-
ever, a major shortcoming is that it lacks activity
against Aspergillus and several non-albicans
Candida species.[20] The recent introduction of
various new broad-spectrum antifungal agents
registered for prophylactic use, such as micafungin
and posaconazole, has increased the number of
possible strategies in high-risk patients.[21-23] In
order to aid decisions concerning which prophy-
lactic agent provides the best value for limited
healthcare resources, it is important to assess the
cost effectiveness of each option. This article will
review the available pharmacoeconomic evidence
regarding antifungal prophylaxis in immuno-
compromised patients treated for haematological
malignancies. Furthermore, we will briefly dis-
cuss specific points of interest concerning cost-
effectiveness analyses of antifungal prophylaxis.
1. Literature Search Strategy
Relevant cost-benefit or cost-effectiveness anal-
yses were collected by conducting a computerized
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search on the PubMed, EMBASE and Web of
Science databases. We searched using the key
words (‘cost’ or ‘economic’) and (‘antifungal’ or
‘invasive fungal infections’ or ‘systemic fungal
infections’) and (‘prophylaxis’ or ‘prevention’ or
‘treatment’ or ‘management’). Searches were carried
out up until the end of September 2010. Further-
more, we manually searched in the references of
identified articles for relevant economic evaluations
not included in the above-mentioned databases.
We included studies if they met the following
criteria: (i) they included a full cost-benefit or cost-
effectiveness analysis (posters and abstracts were
excluded due to a lack of detailed information);
(ii) they were published in peer-reviewed journals
restricted to the English language; and (iii) theywere
economic evaluations on antifungal prophylaxis in
immunocompromised patients treated for hae-
matological malignancies. Accordingly, we excluded
both studies that focused on antifungal (empirical,
pre-emptive or directive) treatment and studies
on antifungal prophylaxis in patients with under-
lying diseases other than haematological malig-
nancies (i.e. HIV/AIDS, organ transplantation).
Studies were not excluded on the basis of their
date of publication.
After excluding reviews, editorials and other
non-original studies, the search strategy highlighted
15 potentially relevant cost-benefit or cost-effec-
tiveness analyses. One study assessed the cost per
successfully treated person comparing alternative
modes of prophylaxis (i.e. oral fluconazole, am-
photericin B and oral polyenes) against oro-
pharyngeal infections.[24] Since oropharyngeal
infections are not defined as systemic or invasive
fungal infections, we excluded this study from
further analyses. Additionally, three other studies
were excluded as they did not include a full cost-
benefit or cost-effectiveness analysis.[25-27] Poirier
et al.[25] estimated the costs of different prophy-
lactic itraconazole dosing regimens only includ-
ing drug acquisition costs, while Sajben et al.[26]
compared only costs of antibacterial treatment
in patients who received prophylaxis (i.e. fluco-
nazole plus ofloxacin) with those who did not.
Al-Badriyeh et al.[27] compared the costs of pro-
phylactic voriconazole versus posaconazole, but
also specifically focused on the cost of drug
therapy and hospitalization, without translating,
in money terms, the health consequences of pro-
phylaxis. This finally left a sample of 11 full eco-
nomic evaluations included in this review.
Table I shows themain characteristics (i.e. year
of publication, underlying disease, interventions
and type of economic analysis) of the included
economic studies. Of the 11 studies, three refer to
the US,[34,36,37] two to Switzerland[28,38] and one
each to theUK,[29] Germany,[31] theNetherlands,[35]
Japan[30] and Korea,[33] and one to both the
Netherlands and Germany.[32] The publication
years ranged from 1995 to 2010, with the majority
(9 of 11) being published after 2005.
2. Description of Selected Studies
The cost effectiveness of a wide variety of
prophylactic agents were covered by the economic
evaluations included in this review (table II).
Schaffner and Schaffner[28] conducted a double-
blind, controlled, single-trial to assess the effect
of fluconazole prophylaxis versus no prophylaxis
in patients undergoing chemotherapy for hae-
matological neoplasis. Besides clinical outcomes,
they focused on healthcare costs related to the
management of fever and infection with data on
resource use being collected alongside the clinical
trial. Their cost-benefit analysis concluded that
fluconazole did not reduce healthcare costs,
which even tended to be higher in the fluconazole
group (not statistically significant).
A cost-benefit analysis was performed by
Wakerly et al.[29] to compare the cost implications
of prophylactic treatment by means of fluconazole
with oral polyenes, a combination of fluconazole
and polyenes, and no prophylaxis. To assess the
clinical outcomes and accompanying costs asso-
ciated with the different prophylactic strategies, a
decision tree was constructed. Data on treatment
effectiveness, clinical outcomes and resource use
were gathered through a literature survey and
clinical interviews conducted in UK hospitals.
Wakerly et al.[29] concluded that all strategies in-
volving prophylaxis are cheaper options than the
‘no prophylaxis’ strategy. The most favourable
prophylactic strategy, however, depends on the
patient group as well as the source (i.e. the literature
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or expert opinion) used for obtaining model
probabilities.
Nomura et al.[30] evaluated the cost effectiveness
of fluconazole prophylaxis compared with em-
pirical treatment with amphotericin B and no
prophylaxis (i.e. only directive antifungal treat-
ment when infection is diagnosed). They performed
a literature survey limited to clinical trials in order
to obtain the clinical parameter values used in the
decision tree. Furthermore, resource use and
Table I. Published economic evaluations on antifungal prophylaxis in immunocompromised patients (pts) treated for haematological
malignancies









Pts with AML, lymphoblastic
leukaemia, or recurrent high-grade
malignant lymphoma who received
intensive chemotherapy
Fluconazole






distinguished: (i) chemotherapy only;




(nystatin 400 000 units/d
+AmB [40 mg/d])






Pts with AML who were neutropenic
as a result of chemotherapy
Fluconazole
(400mg/d PO)
1. Empirical AmB (IV)






High-risk pts with haematological
malignancies (acute leukaemia or
HSCT) and prolonged neutropenia
receiving chemotherapy
Low-dose IV liposomal
AmB prophylaxis (50mg as
a 1-h infusion every other d)
No prophylaxis CBA
de Vries et al.,[32]
Netherlands,
Germany
Immunocompromised pts with acute
leukaemia receiving chemotherapy or
pts receiving a BMT
Itraconazole
(bioavailable dose






(IC per IFI averted)
Sohn et al.,[33]
Korea
Pts receiving an allogeneic HSCT for
any indication, or autologous HSCT
for haematological malignancy
Micafungin
(50mg/d or 1mg/kg IV
in pts weighing <50 kg)
Fluconazole
(400mg/d or 8mg/kg IV





Pts receiving an allogeneic HSCT for
any indication, or autologous HSCT
for haematological malignancy
Micafungin
(50mg/d or 1mg/kg IV
in pts weighing <50 kg)
Fluconazole
(400mg/d or 8mg/kg IV
in pts weighing <50 kg)
CEA




chemotherapy for AML or MDS
Posaconazole
(600mg/d PO)






chemotherapy for AML or MDS
Posaconazole
(600mg/d PO)
Standard azole txa CEA




chemotherapy for AML or MDS
Posaconazole
(600mg/d PO)





chemotherapy for AML or MDSb
Posaconazole
(600mg/d PO)
Standard azole txa CEA
(IC per LYG)
a 81% received fluconazole 400mg/d PO and 19% received itraconazole 400mg/d PO.
b The study further included a decision-tree model with data from HSCT recipients who had developed graft-versus-host disease, but this
analysis is outside of the scope of this article.
AmB =amphotericin B; AML =acute myeloid leukaemia; BMT = bone marrow transplantation; CBA = cost-benefit analysis; CEA = cost-
effectiveness analysis; CUA = cost-utility analysis; HSCT = haematopoietic stem cell transplantation; IC = incremental cost; IFI = invasive
fungal infections; IV = intravenous; LYG = life-year gained; MDS=myelodysplastic syndrome; PO =oral; tx = treatment.
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Table II. Study design and main results of full economic evaluations on antifungal prophylaxis in immunocompromised patients (pts) treated for haematological malignancies. All
studies were conducted from a healthcare payer perspective
Study, year of
values, currency
Analysis [time horizon] Source of efficacy/
effectiveness data











Resource use estimated in RCT;
prices obtained from the hospital
administration or pharmacy
Net benefit= $US3811 (average
cost per pt: fluconazole =
$US35 440, placebo: $US31 559);











labour costs; treatment costs
Resource use based on the
literature and clinical interviews;
unit costs extracted from national
sources
All strategies involving prophylaxis
are less costly options than the ‘no
prophylaxis’ strategy; the most
favourable strategy depends on the
pt group and the data source used
Nomura et al.,[30]
1993, $US











Costs retrieved from hospital
claims of inpatients at a teaching




AmB =$US652 per LYG
Fluconazole vs no prophylaxis and

















individual pts; unit costs
extracted from national sources
Net benefita= h1094 (95% CI 2242,
-53; p =0.061); probability of
positive net benefit =97.4%
de Vries et al.,[32]
2004, h





Resource use obtained from
Dutch databases and expert
opinion; unit costs extracted from
national databases
For both Netherlands and Germany,
itraconazole dominated fluconazole
and no prophylaxis with regard to
the IC per IFI averted; probability of
itraconazole being dominant vs
fluconazole: »98% in both countries
Sohn et al.,[33]
2007, W








Derived from a previously
published economic evaluation
of antifungal treatment in Korea,




with regard to the IC per LYG;
micafungin resulted in 4.8 LYG and




Pt level (estimated costs
applied to individual pts in
RCT) [treatment








Unit costs prophylactic drugs
extracted from national sources;
hospital costs due to IFIs
extracted from the literature
Micafungin dominated fluconazole
with regard to the IC per treatment






















































































Analysis [time horizon] Source of efficacy/
effectiveness data
Cost components Source of cost data Results
Stam et al.,[35]
2006, h
Model [lifetime] Treatment efficacy









Data on length of prophylaxis
obtained from RCT; drug
acquisition costs obtained from
national databases; Dutch costs
related to an IFI obtained from
the literature
Posaconazole dominated standard
azole treatment with regard to the IC
per QALY gained; posaconazole
resulted in 0.08 QALYs gained and
savings of h183 per pt vs standard
azole treatment; estimated
probability of posaconazole being
cost effective at a WTP threshold of





RCT Prophylactic agents; inpatient
costs (i.e. room charges,
radiology, operating room,
drugs, laboratory tests,
supplies, therapy and all
other charges)
Unit costs prophylactic drugs
extracted from national sources;
hospital costs due to IFIs
extracted from literature
Posaconazole dominated standard
azole treatment with regard to the IC
per IFI avoided; posaconazole
resulted in 6% more IFIs averted
and savings of $US2507 per person
vs standard azole treatment during
the treatment phase; estimated
probability of posaconazole being




Model [lifetime] RCT Prophylactic agents; inpatient
costs attributable to an IFI
(one parameter containing all
costs)
Unit costs prophylactic agents
from national databases and
manufacturer; costs attributable
to an IFI extracted from
unpublished healthcare cost data
Posaconazole dominated standard
azole treatment with regard to the IC
per LYG; posaconazole resulted in
0.07 LYG and savings of $US600
per pt vs standard azole treatment;
estimated probability of
posaconazole being dominant: 73%
Greiner et al.,[38]
2006, CHF
Model [lifetime] RCT Prophylactic agents; inpatient




Unit costs prophylactic agents
from national databases; costs
attributable to an IFI extracted
from local statistics, literature
reviews and expert opinion
Posaconazole dominated standard
azole treatment with regard to the IC
per LYG; posaconazole resulted in
0.016 LYG and savings of CHF1118




a Here, net benefit was defined as: net costs no prophylaxis minus net costs L-AmB.
b Two separate analyses were performed.
AmB = amphotericin B; AML =acute myeloid leukaemia; CHF =Swiss franc; dominated =more effective and less costly; IC = incremental cost; IFI= invasive fungal infections;
LOS = length of stay; LYG = life-year gained; MDS =myelodysplastic syndrome; NS =not specified; QOL= quality of life; RCT = randomized controlled trial; W =Korean won;





























































costs were retrieved from hospital claims together
with Japanese reimbursement charges. They con-
cluded that fluconazole prophylaxis appears to
ensure clinical benefits with acceptable cost
effectiveness.
The cost benefit of low-dose L-AmBprophylaxis
was assessed by Penack et al.[31] Data on resource
use were retrospectively gathered for patients who
recently were included in a randomized control-
led trial (RCT) comparing L-AmB with no pro-
phylaxis. Costs associated with medication and
diagnostic tests were valued using German market
prices and the German cost catalogue for hospital-
based procedures, respectively. The authors con-
cluded that the use of L-AmB prophylaxis in
high-risk patients could result in significant cost
savings compared with no prophylaxis.
de Vries et al.[32] designed a decision analytic
model to assess the cost effectiveness of itraco-
nazole compared with both fluconazole and no
prophylaxis for the prevention of IFIs. Effec-
tiveness measures for the different strategies in
terms of the risk of acquiring an IFI were ex-
tracted from previously published meta-analyses.
Furthermore, estimates of medical resource use
due to an IFI were obtained from a retrospective
cohort study and expert opinions. Subsequently,
national unit costs were linked to these resources.
de Vries et al.[32] concluded that itraconazole was
likely to result in improved outcomes and lower
costs compared with fluconazole and no pro-
phylaxis in both the Netherlands and Germany.
The cost effectiveness of prophylaxis with mi-
cafungin versus fluconazole was estimated by
Sohn et al.[33] and Schonfeld et al.[34] They both
used efficacy data obtained from a large RCT.[39]
Schonfeld et al.[34] performed the analysis for the
US situation, while Sohn et al.[33] used theKorean
national health insurance perspective. The former
used published literature to directly obtain US
cost estimates associated with the different clin-
ical outcomes in order to estimate the cost per
treatment success after linking those cost esti-
mates to the individual clinical outcomes in the
clinical trial. On the other hand, Sohn et al.[33]
constructed a decision analytic model that in-
cluded Korean data on costs and life expectancy
to assess the costs per life-year gained (LYG).
Although both studies[33,34] evaluated the cost
effectiveness for two different countries and used
different outcome measures (i.e. costs per treat-
ment success and costs per LYG), they both es-
timated micafungin to be the dominant strategy
(i.e. more effective and cost saving).
Finally, Stam et al.,[35] Collins et al.,[36]
O’Sullivan et al.[37] and Greiner et al.[38] assessed
the cost effectiveness of posaconazole for pro-
phylactic treatment in comparison with standard
azole prophylactic treatment. All four based their
analysis on an RCT conducted by Cornely
et al.,[40] where, in the comparator arm 81% of the
patients received fluconazole and 19% received
itraconazole. Furthermore, all four designed a
decision analytic model in order to include data
from several data sources. Unlike Collins et al.,[36]
who considered the incremental cost per IFI avoid-
ed, Stam et al.,[35] O’Sullivan at al.[37] and Greiner
et al.[38] extended their decision analytic models
with a Markov model to allow estimation of
QALYs gained[35] or LYG.[37,38] Although the
analyses were conducted for different countries
and used different outcome measures, the con-
clusions drawn by the four different papers were
similar; they all concluded that posaconazole is
likely to be a cost-effective alternative relative to
fluconazole or itraconazole, and may result in
cost savings.
3. Comparison of Studies
As shown in table I and described in the previous
sections, the economic evaluations examined awide
variety of treatment options in different patient
populations. The cost benefit or cost effectiveness
of antifungal prophylaxis with amphotericin B,
fluconazole, itraconazole, micafungin and posa-
conazole have all been estimated.[28-39] Further-
more, a diversity of comparators were included in
these economic analyses. The antifungals that have
already been on the market for a considerable
number of years now (i.e. fluconazole, amphote-
ricin B and itraconazole) were all compared with
no prophylaxis.[28-32] In addition to the comparison
with no prophylaxis, two studies explicitly com-
pared fluconazole prophylaxis with oral polyenes
and empirical treatment with amphotericin B,
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respectively.[29,30] Until a few years ago, ‘no pro-
phylaxis’ was the standard strategy (i.e. existing
care) in many institutions. Consequently, the no
prophylaxis strategy was an appropriate com-
parator at that time. However, as antifungal
prophylaxis is currently recommended and used
in many institutions for patients at high risk of in-
fection, new prophylactic agents should no longer
be compared only with no prophylaxis.[18,19] The
recently introduced prophylactic agents micafungin
and posaconazole have been compared with flu-
conazole and ‘standard azole treatment’ (fluco-
nazole or itraconazole), respectively.[33-38]
The economic evaluations were performed for
different patient populations at risk for acquiring
IFIs (table I). For simplicity, these patients are
often roughly divided into the following two cate-
gories: (i) patients with haematological malignancies
treated with chemotherapy; and (ii) patients under-
going anHSCT (i.e. bonemarrow transplantation).
Six studies[28,30,35-38] focused on immunocompro-
mised patients treated with chemotherapy, two
studies[33,34] focused only on patients undergoing
a bone marrow transplantation and three studies
included both patient groups.[29,31,32] However,
only one of those stratified and performed sepa-
rate analyses for the two groups.[29] It is important
to note that one should be cautiouswhen combining
different patient groups, as the underlying disease
has an important influence on baseline IFI incidence
rates. Therefore, we strongly discourage the gen-
eralization of pharmacoeconomic results from
one patient group to another. We will extensively
elaborate on the influence of IFI incidence rates
on the cost effectiveness of prophylactic regimens
in section 5.
The included economic evaluations did not
only look at different prophylactic agents and
different patient populations, they also differed
considerably with respect to evaluation type, time
horizon and efficacy and cost data included. In
general, there are two main approaches for data
collection and analysis in economic evaluations.[41]
One could perform an analysis using patient-level
data, which are usually gathered alongside clin-
ical trials, or using decision analytic modelling,
where data are drawn from a number of sources.
Three of the 11 economic evaluations used patient-
level data to estimate the cost effectiveness.[28,31,32]
When using patient-level data, one would ideally
collect prospective data on efficacy and resource
use simultaneously alongside an RCT, as Schaffner
and Schaffner[28] did in their cost-benefit analysis.
However, Penack et al.[31] collected the economic
data retrospectively for the patients included in
an RCT, while Schonfeld et al.[34] obtained cost
estimates from the literature and linked those to
the individual clinical outcomes assessed in anRCT.
The other economic evaluations all designed a
decision analytic model to bring evidence on treat-
ment effectiveness and costs from a range of sources
together.[29,30,32,33,35-38] Most of these modelling
studies obtained efficacy data only from one
RCT.[33-38] However, de Vries et al.[32] performed
a formal meta-analysis, which is generally accepted
as the highest level of evidence, to estimate the effi-
cacy of different prophylactic treatment modalities.
The appropriate time horizon for an economic
evaluation should be the period over which the
costs and/or the effects (i.e. treatment effects and
adverse effects) of the treatment options being
compared might differ.[41] In the case of anti-
fungal prophylaxis, the appropriate time horizon
refers to the period a patient is at risk of an IFI
and receives prophylactic or directed treatment.
Most of the selected evaluations used this time
horizon, by estimating costs and effects that oc-
curred during the neutropenic period while on
treatment.[28,29,31,32,34,36] Some also included a
post-treatment period of a few weeks in their time
horizon.[34,36] However, for a more generic cost-
effectiveness measure, such as costs per LYG, one
should take a time horizon that reflects a patient’s
entire lifetime. Five cost-effectiveness analyses
included background survival probabilities in
their models in order to estimate differences in
mean survival rates between different treatment
strategies, taking the underlying disease into ac-
count.[30,33,35,37,38] Stam et al.[35] also included
morbidity in the form of utilities in their analyses
and assessed the costs per QALY gained. How-
ever, no quality of life loss as a result of an IFI
was included; only utilities of the underlying con-
dition were taken into account.[35] Although one
would ideally include both, to our knowledge no
quality weights associated with IFIs have yet
744 Pechlivanoglou et al.
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been published in the literature. This certainly is
an area for further research.
According to national guidelines, costs and
effects that will be incurred in the future should
be discounted because of time preferences.[41] In
view of the fact that costs related to antifungal
prophylaxis and IFIs (i.e. treatment, diagnostic
procedures and length of stay) will be incurred
within the first year following the start of prophy-
lactic treatment, discounting on costs is redundant
here. This obviously also applies for effects (e.g.
the number of IFIs) that occur within the first
year.However, if the cost per LYGorQALYgained
is the cost-effectiveness measure of interest, life-
years or QALYS should be appropriately dis-
counted. Although Stam et al.[35] applied annual
discount rates of 1.5% for QALYs, and O’Sullivan
et al.[37] and Greiner et al.[38] applied annual dis-
count rates of 3% for life-years, Nomura et al.[30]
and Sohn et al.[33] did not discount future life-
years. Greiner et al.[38] and O’Suliivan et al.[37] did
mention that they discounted with a 3% rate;
however, the costs used in their analysis do not
necessitate discounting.
All relevant direct medical costs associated
with both antifungal prophylaxis and the diagnosis
and treatment of IFIs should ideally be included
in economic evaluations concerning antifungal
prophylaxis. Except one,[31] all of the studies re-
viewed in this article more or less covered these
key components.[28-30,32-38] Although Penack et al.[31]
performed a separate analysis comparing length
of stay in different care units, they did not include
costs related to an increase in length of stay due
to an IFI in their cost-benefit analysis. This is a
fundamental flaw, as these hospitalization costs
are indicated as a main determinant of the total
direct medical costs.[14]
In all studies, costs of prophylactic drug use
were obtained by multiplying days on prophylactic
treatment by national unit costs. Estimates of
direct medical costs associated with an IFI (i.e.
diagnostic procedures, treatment and length of
stay) were obtained through a variety of methods
in the different studies.[41] As mentioned earlier in
this section, in their cost-benefit analyses Schaffner
and Schaffner[28] prospectively and Penack et al.[31]
retrospectively gathered patient data on resource
use from a single RCT. Subsequently, in order
to obtain individual cost estimates, resource use
was valued by using national unit costs.[28,31] In
modelling studies, one wants to link a mean cost
estimate to every disease state. Nomura et al.[30]
and Sohn et al.[33] directly obtained cost estimates
from hospital claims and national health insurance
databases, respectively. The latter, moreover, in-
cluded additional medical costs obtained from
the literature for costs not available in the Korean
national health insurance database. Furthermore,
the three studies performed in the US[34,36,37]
based their cost estimates on case-control studies
where incremental hospitalization costs due to an
IFI were estimated by comparing the costs in a
group of patients who experienced an IFI (cases)
with a group of patients who did not (controls).
Obviously, patients were matched on underlying
conditions. This is potentially the most appro-
priate way, as long as the matching procedure has
been done correctly, to estimate the incremental
costs as all differences in resource use or costs
between two groups are able to be included.
Schonfeld et al.[34] and Collins et al.[36] extracted
their cost estimates from a published cost-of-
illness study,[14] while O’Sullivan et al.[37] performed
the cost estimation themselves by using un-
published data. Note that Schonfeld et al.[34] did
not design a model for estimating cost effective-
ness, but linked the cost estimates to individual
patient outcomes in order to perform an analysis
on patient-level data. Another way of obtaining
cost estimates when data on resource use or costs
are lacking for a specific situation (e.g. country) is
to derive resource use estimates from clinical ex-
pert opinions and subsequently value these by
using national unit costs. Four studies (partly)
based their resource use estimates on expert opi-
nions.[29,32,35,38] Wakerly et al.[29] performed two
separate analyses in which they used either lit-
erature sources or expert opinions to obtain esti-
mates of resource use. Stam et al.[35] combined
estimates of short-term resource use obtained from
clinical trial data with long-term resource use es-
timates from expert opinions. Besides length of
hospital stay, de Vries et al.[32] also derived re-
source use estimates from clinical experts. They
conducted a case-control study to estimate the
Antifungal Prophylaxis in Haematological Malignancies 745
ª 2011 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2011; 29 (9)
increased length of stay due to an IFI by using
hospital data.[32] Greiner et al.[38] also combined
clinical trial data with literature sources and expert
opinion in order to define estimates of resource use.
Although not always explicitly stated, all the
included cost-benefit and cost-effectiveness stud-
ies were performed from a healthcare payer’s
perspective (table II). This means that possible
benefits/costs due to production gains/losses were
not taken into account.[41] Recent international
guidelines for pharmacoeconomic research[42]
indicate that the societal perspective should be
preferred. However, we believe that the omission
of indirect costs due to productivity losses is le-
gitimized in this situation as these seriously ill
patients are probably already absent from work
because of their underlying disease. In other words,
as these indirect costs will not be substantial, the
healthcare perspective matches the societal per-
spective in these patients.
Finally, a sound pharmacoeconomic analysis
should always include an assessment of the un-
certainty surrounding the economic outcomes that
result from the uncertainty in the input parameter
values.[41,43,44] This can be done either by using
parametric or non-parametric, resampling, meth-
ods when economic outcomes are estimated using
patient-level data or by using sensitivity analysis
when these outcomes are based on a decision
theoretic model. The three economic evaluations
that were based on patient-level data all report
confidence intervals around the estimated cost-
benefit[28,31] or cost-effectiveness[34] outcomes.
Penack et al.[31] and Schonfeld et al.[34] stated that
they used a non-parametric bootstrap method,
while Schaffner and Schaffner[28] did not elabo-
rate on the method used. The advantage of non-
parametric bootstrapping is that no assumptions
of the underlying distribution are made.[45] This
makes these methods particularly suitable for es-
timating confidence intervals around incremental
cost-effectiveness ratios, because of the statistical
characteristics of this ratio.
Nowadays, probabilistic sensitivity analysis
(PSA) is the method of choice in order to handle
parameter uncertainty in decision models. For
instance, in the UK, the National Institute for
Health and Clinical Excellence (NICE) guidelines
state that a PSA should be employed to character-
ize uncertainty.[44] However, three of the model-
ing studies included in this review lack a PSA and
only performed multiple univariate sensitivity
analyses to assess the impact on cost effectiveness
of changing one variable at a time.[29,30,33] Never-
theless, it is very important to assess the joint
uncertainty in all parameters by using PSA, as it
is this overall uncertainty that could have important
implications for medical decision making. The
other five modeling studies indeed include both
multiple univariate sensitivity analyses and a
PSA.[32,35-38] The quality of the PSA, however,
varied among studies. A brief description of the
requirements necessary for a valid and relevant
PSA is presented in Drummond et al.[41] de Vries
et al.[32] presented in detail the method followed
for the conduction of the PSA; however, no dis-
tributional assumptions regarding the costs of
treatment or hospitalization are mentioned. Collins
et al.[36] briefly mentioned the conduction of a PSA
and did not report any distributional assump-
tions around the parameter uncertainty. In con-
trast, the PSA conducted in Stam et al.,[35] Greiner
et al.[38] and O’Sullivan et al.[37] are clearly pre-
sented and in accordance with the criteria set by
Drummond et al.[41]
4. Summary of Results
Two reviews have previously been published
that discuss the available evidence on the cost ef-
fectiveness of antifungal prophylaxis in suscep-
tible patients.[46,47] In 2004, Dixon et al.[46] not only
focused on patients with haematological malig-
nancies but also included many different patient
populations, such as HIV/AIDS patients, cancer
patients and transplant recipients. They con-
cluded that they were unable to find a coherent
body of evidence for any particular patient group
and/or indication.[46] Furthermore, they touched
on the poor quality of the studies included in their
review. However, the two studies[28,29] that also
met our inclusion criteria and that were therefore
also included in our review, scored above average
(i.e. decent quality).
In 2006,Moeremans andAnnemans[47] summar-
ized the available evidence of health economic
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knowledge of antifungal treatment. As opposed
to Dixon et al.,[46] they only included neutropenic
patients in their review.[47] With regard to pro-
phylaxis, they concluded that, since 2004, the
pharmacoeconomic evidence had not been ex-
panded and, therefore, economic data to support
recommendations for prophylactic drug thera-
pies were still lacking at that time.[47] However, as
noted in previous sections, most full cost-effec-
tiveness studies on antifungal prophylaxis have
been published since 2006.[30-38]
One should bear in mind that the cost benefits
or cost effectiveness of antifungal prophylaxis de-
pends considerably on several factors other than
the specific prophylactic agent. As wide varia-
tions exist in studies regarding patient character-
istics, underlying diseases, hospital settings, drug
regimens and study methods, it is difficult to find
clear evidence of the economic advantages of a
single prophylactic agent. Furthermore, one agent
could be the most economic strategy under par-
ticular circumstances (e.g. specific patient group
in a particular country), while it is exceeded by
others under different circumstances. Therefore,
we strongly advise against indiscriminately gen-
eralizing conclusions from economic analyses of
antifungal prophylactic drugs.We will extensively
ground this with an example in the next section.
However, some general lessons can be learned
from the studies included in this review. First,
antifungal prophylaxis is potentially a (highly)
economically favourable intervention. Four of
five studies that compared fluconazole, ampho-
tericin B or itraconazole with no prophylaxis es-
timated the prophylactic intervention to be cost
beneficial,[29,31] cost effective[30] or even cost sav-
ing,[32] while the other study[28] did not reveal any
statistical difference in economic outcomes (table
II). As IFIs are associated with significant mor-
tality and expensive treatment, carefully targeted
antifungal prophylaxis could considerably reduce
treatment costs and increase life expectancy.[13-15]
Obviously, the economic advantages of prophy-
laxis highly depends on baseline IFI incidence rates.
Furthermore, the newer antifungal agents seem
to be potentially more cost effective than fluco-
nazole, which is still being used as the prophy-
lactic agent of choice in many institutions. Both
itraconazole and micafungin have been estimated
as cost saving relative to fluconazole.[32-34] Further-
more, posaconazole has been estimated as cost
saving compared with standard azole treatment
(i.e. 81% received fluconazole and 19% received
itraconazole).[35-38] As mentioned previously, re-
garding micafungin and posaconazole, it is im-
portant to note that the clinical effectiveness
measures used in several cost-effectiveness studies
were obtained from the same single RCT.[39,40]
In other words, differences in incremental cost-
effectiveness outcomes between the two studies
on micafungin or the four studies on posacona-
zole originate from different cost estimates or
different (country-specific) life expectancies.
Next to the above-mentioned antifungal agents,
voriconazole is also often used in practice as
an agent for antifungal prophylaxis in immuno-
compromised patients. However, evidence arising
from RCTs that prove its relative effectiveness as
a prophylactic agent is not yet publicly available.
For that reason, the economic evaluation of
prophylaxis with fluconazole is hard to implement.
Al-Badriyeh et al.[27] conducted a pharmaco-
economic evaluation of antifungal prophylaxis
with voriconazole versus prophylaxis with posa-
conazole. The authors drew their efficacy and
effectiveness data from a targeted retrospective
chart review. Their evaluation approach, how-
ever, was closer to a cost comparison analysis
than a cost-benefit analysis, which precluded the
inclusion of this study in our systematic review.
The advantage of itraconazole, micafungin
and posaconazole is that they, unlike fluconazole,
show activity against Aspergillus species.[20] This
explains the large potential benefits in terms of
cost effectiveness of these newer antifungal agents
compared with fluconazole.[32-38] As Aspergillus
infections are associated with very high mortality
rates and are most costly to treat, obviously, these
drugs are potentially able to save both more costs
and more life-years than fluconazole.[13,14] In other
words, the higher investment costs of using the
more expensive newer drugs could possibly be
totally offset by the averted costs. Furthermore,
the increase in the incidence of mould infections
further highlights the importance of preventing
these Aspergillus infections.[11] However, as holds
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true for all types of IFIs, it depends on the specific
patient group together with the specific hospital
setting as to what the exact IFI incidence rate will
be and which prophylactic strategy will be most
cost effective.
5. General Remarks on the Cost
Effectiveness of Antifungal Prophylaxis
As applies for all prevention programmes, the
cost effectiveness of antifungal prophylaxis is
highly dependent on the baseline IFI incidence
rate.[48] The baseline IFI rate refers to the number
of cases in a situation where no antifungal prophy-
laxis is given. Obviously, the higher the baseline
IFI incidence rate, the more IFIs and associated
mortality, morbidity and costs could be prevented
by using prophylaxis. Hence, the baseline in-
cidence rate can have a large impact on the cost
effectiveness of antifungal prophylaxis. This effect
can also have important implications for medical
decision making. In the Netherlands, interven-
tions are considered certainly cost effective if their
estimated cost effectiveness is below a threshold
of h20 000 per LYG.[49] Although this threshold
is informal and not undisputed, it is often used by
decisionmakers. From a pharmacoeconomic point
of view, this means that, in the Dutch situation,
antifungal prophylaxis with drug A would be
considered cost effective versus no prophylaxis if
the baseline IFI incidence rate was assumed to be
10% (incremental cost per LYG h2000), while
it would not be considered cost effective if the
baseline IFI incidence rate was assumed to be 3%
(incremental cost per LYG h30 000). This example
assumes per-patient costs for antifungal prophy-
laxis with drug A of h1500 and treatment of IFI
of h25 000; assumed clinical outcomes were a life
expectancy of 5 years in patients without IFI, a
mortality rate in patients with IFI of 50%, and an
effectiveness rate of antifungal prophylaxis with
drug A of 50%.
There are several factors that affect the base-
line incidence rate of IFIs and consequently act
on the cost effectiveness of antifungal prophylaxis.
First, a number of patient-specific risk factors for
the development of IFIs have been identified.[3,9]
For the major part, these are associated with the
underlying disease and accompanying treatment.
It is important to note that risk factors can differ
depending on the fungus. For example, severe
gastrointestinal damage will highly increase the
risk of acquiring an invasive Candida infection,
while this has no impact on the risk of acquir-
ing an Aspergillus infection.[3] Obviously, as the
probability of acquiring an IFI (i.e. baseline IFI
incidence rate) will be higher in high-risk patients,
the cost effectiveness of antifungal prophylaxis in
high-risk patients will be more favourable than in
low-risk patients. Consequently, we strongly dis-
courage generalizing cost-effectiveness results
from one patient group to another.
Second, as also applies for several infectious
diseases caused by bacteria or viruses, significant
geographical differences in the epidemiology of
IFIs were found.[3,50] Baseline IFI incidence rates
vary not only from region to region, but even
from hospital to hospital. Consequently, the use
of a particular prophylactic agent in a particular
patient population could be cost effective in one
country/region, while it will not be cost effective
in the same patient population in another country/
region. Although the same model structure can
often be used for different countries, one should
always use specific geographical IFI incidence
data to obtain valid cost-effectiveness results.
Finally, the sustained use of antifungal pro-
phylaxis can influence the (geographical) infection
patterns of both moulds and yeasts. The success-
ful use of fluconazole has, for example, caused a
shift from azole-susceptible species to less sus-
ceptible and even azole-resistant ones.[9] These
changing patterns in IFIs, together with the local
variability in infection rates, can have important
consequences for the cost effectiveness of parti-
cular prophylactic agents. In our example in the
Dutch situation, we estimated the incremental
cost effectiveness of antifungal prophylaxis with
drug A versus no prophylaxis, but the influence
of baseline IFI incidence rates on the incremental
cost effectiveness will, of course, also be present if
two different prophylactic agents are compared.
For example, in areas where IFIs are predominantly
caused byAspergillus species, it is evident that the
newer antifungal agents (i.e. itraconazole, posaco-
nazole or micafungin) that show activity against
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these Aspergillus species become pharmacoecono-
mically more favourable than fluconazole.
In summary, it is important to be aware that
the cost effectiveness of a particular antifungal
prophylactic agent depends on several crucial
aspects. This should be kept in mind when com-
paring the results of different economic evalua-
tions or when generalizing the results from one
patient population or setting to another.
6. Conclusion
Considering the available evidence, antifungal
prophylaxis in immunocompromised patients
treated for haematological malignancies seems to
be an intervention with favourable cost-benefit,
cost-effectiveness and cost-saving potential. Fur-
thermore, the newer recently introduced anti-
fungal agents seem to be an attractive alternative
to fluconazole from a pharmacoeconomic point
of view. However, due to a wide heterogeneity
regarding patient characteristics, underlying dis-
eases, hospital settings and study methods in the
included economic studies, as well as the lack of
‘head-to-head’ trials, it is difficult to find clear
evidence of the economic advantages of a single
prophylactic agent.
In the past years, new antifungal agents such
as micafungin and posaconazole have been ap-
proved for clinical use.[21] Unfortunately, these
drugs have not yet been compared with each other
in one single clinical trial. Other antifungals are
in different stages of development prior to ap-
proval.[5] For example, ravuconazole and isavu-
conazole are new triazoles that could possibly be
used for antifungal prophylaxis in the future.[51]
Due to the rapid successive market entry of these
antifungal prophylactic strategies, (clinical) trials
including all relevant comparator interventions
will often be lacking at the time of registration.
However, a sound cost-effectiveness analysis in-
cluding all relevant strategies is required in order
to assess which strategy gives best value for
money. Therefore, indirect and mixed treatment
comparison methods could have great potential
for estimating the comparative cost effectiveness
of multiple antifungal prophylactic options using
evidence from trials that individually do not com-
pare all treatment options.[52] Such a mixed treat-
ment comparison has recently been performed for
estimating the cost effectiveness of antifungal
treatment for invasive Candida infections.[53]
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